RBC Capital Maintains Outperform on Pacira BioSciences, Lowers Price Target to $37

Benzinga · 07/31/2024 14:16
RBC Capital analyst Gregory Renza maintains Pacira BioSciences (NASDAQ:PCRX) with a Outperform and lowers the price target from $42 to $37.
Recently
Symbol
Price
%Change
    FN
  • 208.10
  • -0.86%